Cost Effectiveness of Ruxolitinib Versus Best Available Therapy For The Treatment of Myelofibrosis From Public Health Perspective In Chile
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1404
https://www.valueinhealthjournal.com/article/S1098-3015(16)32770-X/fulltext
Title :
Cost Effectiveness of Ruxolitinib Versus Best Available Therapy For The Treatment of Myelofibrosis From Public Health Perspective In Chile
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32770-X&doi=10.1016/j.jval.2016.09.1404
First page :
A590
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1319